^
    Back
    Association details:
    Biomarker:FGFR4 V550L
    Cancer:Rhabdomyosarcoma
    Drug:ABSK012 (FGFR4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    AACR 2023
    Title:

    LB328 / 19 - Discovery & characterization of a next-generation FGFR4 inhibitor overcoming resistant mutations

    Published date:
    03/15/2023
    Excerpt:
    More importantly, in a RMS PDX xenograft harboring FGFR4 V550L mutation, ABSK012 also showed significant anti-tumor activity….ABSK012, presented here by Abbisko Therapeutics, is a highly potent, selective, and next-generation small molecule FGFR4 inhibitor overcoming FGFR4 mutations resistant to first-generation inhibitors.